MDCX (Medicus Pharma) 3-Year EBITDA Growth Rate: -139.30% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDCX Medicus Pharma Ltd MDCX
12 GF Score
Price $0.27
! 2 Warning Signs
View Full Analysis

What is Medicus Pharma 3-Year EBITDA Growth Rate?

Medicus Pharma MDCX -1.03% 12 3-Year EBITDA Growth Rate is -139.30% as of Jun. 2026. GuruFocus rates MDCX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 808 Drug Manufacturers companies, Medicus Pharma ranks worse than 99.38% on this metric.

Medicus Pharma's EBITDA per Share for the three months ended in Jun. 2026 was $-0.21.

During the past 3 years, the average EBITDA Per Share Growth Rate was -139.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medicus Pharma was -68.90% per year. The lowest was -139.30% per year. And the median was -104.10% per year.

Medicus Pharma  (NAS:MDCX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Medicus Pharma 3-Year EBITDA Growth Rate Related Terms

MDCX vs NSRX, MIRA, SCLX: 3-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - General subindustry, Medicus Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicus Pharma 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicus Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Medicus Pharma's 3-Year EBITDA Growth Rate falls into.


MDCX
12GF Score
Medicus Pharma Ltd MDCX
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicus Pharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of -139.30% mean?
Medicus Pharma (MDCX) has a 3-Year EBITDA Growth Rate of -139.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medicus Pharma and its competitors. According to the industry distribution chart, Medicus Pharma ranks #803 out of 808 companies in the Drug Manufacturers industry, placing it in the top 99.4%.
Is Medicus Pharma's 3-Year EBITDA Growth Rate too high?
Medicus Pharma's current 3-Year EBITDA Growth Rate is -139.30%. Based on the distribution chart, Medicus Pharma ranks #803 out of 808 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicus Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medicus Pharma's 3-Year EBITDA Growth Rate compare to NSRX and MIRA?
According to the Drug Manufacturers industry distribution chart, Medicus Pharma ranks #803 out of 808 companies for 3-Year EBITDA Growth Rate. This places Medicus Pharma in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medicus Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicus Pharma's current 3-Year EBITDA Growth Rate is -139.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicus Pharma stock overvalued right now?
Medicus Pharma (MDCX) has a current 3-Year EBITDA Growth Rate of -139.30%. The current 3-Year EBITDA Growth Rate is -139.30%. Medicus Pharma's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medicus Pharma (MDCX), the current 3-Year EBITDA Growth Rate is -139.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicus Pharma Business Description

Address 100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
12GF Score

Get the complete analysis for MDCX

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price